Emergex has secured a ‘state-of-the-art’ research and development (R&D) facility and hired a new chief scientific officer to drive development of its vaccines.
News
Keytruda combination found to reduce risk of death in RCC
MSD’s Keytruda in combination with Pfizer’s Inlyta has been found to reduce the risk of death by nearly half in patients with advanced renal cell carcinoma (RCC).
NovaBiotics given £1.8m to advance Novamycin
NovaBiotics has been awarded £1.8 million in small business research innovation grant funding to advance its antifungal drug candidate, Novamycin.
Opdivo shows promising results in Phase I/II trial
An early-stage trial has shown promising results for Bristol-Myers Squibb’s Opdivo in combination with Nektar Therapeutics’ bempegaldesleukin as first-line treatment for urothelial carcinoma.
EMA suspends fenspiride medicines due to heart rhythm risks
The EMA has announced an EU-wide suspension of fenspiride medicines due to a potential risk of heart rhythm problems.
UCB to form a research satellite facility within King’s College London
UCB has expanded its global satellite research site strategy with a new research and development collaboration agreement with King’s College London, UK.
Innovate UK awards AKLRD £675,000 for osteoarthritis drug
AKL Research and Development’s early-stage osteoarthritis drug has won a prestigious award from Innovate UK, as a potential “game-changing” treatment.
Darolutamide shows promise for treatment of prostate cancer
Orion’s and Bayer’s darolutamide has shown substantial efficacy in the treatment of prostate cancer.
MSD testing Keytruda combos for prostate cancer
MSD has announced plans to start three late-stage studies of Keytruda in patients with metastatic castration-resistant prostate cancer.
Opdivo/Yervoy combo successful in castration-resistant prostate cancer
A combination of Bristol-Myers Squibb’s Opdivo and Yervoy has shown a significant response in patients with metastatic castration-resistant prostate cancer.
Rexulti falls short of goal in late-stage bipolar disorder studies
Lundbeck’s Rexulti has failed to achieve the primary endpoint of two Phase III bipolar disorder studies.
Alunbrig recommended by NICE for non-small-cell lung cancer
NICE has recommended use of Alunbrig for treating ALK-positive advanced non-small-cell lung cancer after Xalkori on the NHS in England and Wales.
Trajenta meets primary endpoint in CAROLINA trial
Eli Lilly and Boehringer Ingelheim’s Trajenta has been found to demonstrate no increased cardiovascular risk compared to glimepiride in adults with type II diabetes and cardiovascular risk.
Could AI predict survival of ovarian cancer patients?
Researchers have created new AI machine learning software that can forecast the survival rates and response to treatments of patients with ovarian cancer.
NICE changes its mind on Perjeta
NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.
